Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.

Private Company Edition: The venture capital firm said it will back biopharma, diagnostics and other opportunities in health care. In addition to the Design and TScan mega-rounds, Verve raised $94m, Vera garnered $80m and Ixaka (formerly Rexgenero) closed a £40m ($54.7m) financing.